Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Asociación para Evitar la Ceguera en México |
---|---|
Information provided by: | Asociación para Evitar la Ceguera en México |
ClinicalTrials.gov Identifier: | NCT00566761 |
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
Condition | Intervention | Phase |
---|---|---|
Macular Edema Central Retinal Vein Occlusion |
Drug: bevacizumab and triamcinolone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Historical Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion |
Estimated Enrollment: | 10 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | March 2008 |
Comparison of two groups with different treatment with registrations of outcome in BCVA and complications
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Carmen Conzalez-Mijares, Physician | 5517638245 | cacegomi@hotmail.com |
Mexico, Coyoacan | |
Asociacion Para Evitar la Ceguera en Mexico | Recruiting |
Mexico city, Coyoacan, Mexico, 04030 | |
Contact: Retina Department 5510841400 ext 1171 retinamex@yahoo.com |
Principal Investigator: | Carmen Gonzalez-Mijares, Physician | APEC |
Study Director: | Hugo Quiroz-Mercado, Retinologyst | APEC |
Study Chair: | Juan Manuel Jimenez Sierra, Retinologyst | APEC |
Study Chair: | MA Martinez-Castellanos, Physician | APEC |
Study Chair: | Octavio Burgos Vejar, Physician | APEC |
Study Chair: | Raul Velez-Montoya, Physician | APEC |
Study Chair: | Ma de Lourdes Lopez Ramos, Physician | APEC |
Study Chair: | Omar Honerlager, preresident | APEC |
Responsible Party: | Asociación para Evitar la Ceguera en Mexico IAP ( Carmen Cecilia Gonzalez Mijares ) |
Study ID Numbers: | MECRVO |
Study First Received: | November 30, 2007 |
Last Updated: | November 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00566761 |
Health Authority: | Mexico: Ethics Committee |
Macular edema central retinal vein occlusion bevacizumab triamcinolone |
Eye Diseases Vascular Diseases Retinal Degeneration Edema Macular Degeneration Triamcinolone diacetate Bevacizumab Thrombosis Triamcinolone hexacetonide Macular Edema |
Signs and Symptoms Embolism and Thrombosis Triamcinolone Acetonide Embolism Retinal Vein Occlusion Triamcinolone Neoplasm Metastasis Venous Thrombosis Retinal Diseases Retinal degeneration |
Anti-Inflammatory Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Enzyme Inhibitors Glucocorticoids |
Hormones Immunosuppressive Agents Angiogenesis Inhibitors Pharmacologic Actions Therapeutic Uses Cardiovascular Diseases Growth Inhibitors Angiogenesis Modulating Agents |